Inventor · disambiguated record
David R. Clemmons
Also filed as: CLEMMONS DAVID · CLEMMONS DAVID R
13 granted patents·7 pending applications·64 citations·filing 1995–2019
90Inventor score
Files withUNIV NORTH CAROLINA CHAPEL HILL6CLEMMONS DAVID R5UNIV NORTH CAROLINA5AMOLYT PHARMA2AMGEN INC1
Top patents by PatentIndex Score
20 records- 0190US8613922B2Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)CLEMMONS DAVID R·Filed 2011·Granted Dec 24, 2013·14 cites·4 claims
- 0288US9475882B2Antagonists of IAP-SHPS1 interactionUNIV NORTH CAROLINA CHAPEL HILL·Filed 2013·Granted Oct 25, 2016·9 cites·17 claims
- 0386US7723483B2Method for enhancing or inhibiting insulin-like growth factor-IUNIV NORTH CAROLINA·Filed 2005·Granted May 25, 2010·10 cites·17 claims
- 0485US8206706B2Method for enhancing or inhibiting insulin-like growth factor-ICLEMMONS DAVID R·Filed 2009·Granted Jun 26, 2012·8 cites·3 claims
- 0583US8187595B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-ICLEMMONS DAVID R·Filed 2009·Granted May 29, 2012·6 cites·7 claims
- 0676US9073996B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)UNIV NORTH CAROLINA·Filed 2013·Granted Jul 7, 2015·2 cites·5 claims
- 0774US9068000B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-ICLEMMONS DAVID R·Filed 2012·Granted Jun 30, 2015·2 cites·7 claims
- 0863US9220746B2Compounds and methods for treating bone disorders and controlling weightCLEMMONS DAVID R·Filed 2010·Granted Dec 29, 2015·2 cites·19 claims
- 0963US2010215640A1Method for inhibiting cellular activation by insulin-like growth factor-1UNIV NORTH CAROLINA·Filed 2009·Application pending·0 cites
- 1056US5973115AMethod for potentiating and inhibiting insulin-like growth factor activityAMGEN INC·Filed 1995·Granted Oct 26, 1999·11 cites·2 claims
- 1154US2017114134A1Antagonists of iap-shps1 interactionUNIV NORTH CAROLINA CHAPEL HILL·Filed 2016·Application pending·0 cites
- 1254US2008160013A1Method for inhibiting cellular activation by insulin-like growth factor-1UNIV NORTH CAROLINA·Filed 2007·Application pending·0 cites
- 1353US9587024B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)UNIV NORTH CAROLINA CHAPEL HILL·Filed 2015·Granted Mar 7, 2017·0 cites·35 claims
- 1453US2016297866A1Method for inhibiting cellular activation by insulin-like growth factor-1UNIV NORTH CAROLINA CHAPEL HILL·Filed 2016·Application pending·0 cites
- 1552US2016039897A1Compounds and methods for treating obesity and controlling weightUNIV NORTH CAROLINA·Filed 2014·Application pending·0 cites
- 1652US2018016340A1Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor 1 (IGF-1)UNIV NORTH CAROLINA CHAPEL HILL·Filed 2017·Application pending·0 cites
- 1751US9868787B2Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-IUNIV NORTH CAROLINA CHAPEL HILL·Filed 2015·Granted Jan 16, 2018·0 cites·12 claims
- 1849US10947285B2Compounds, compositions and uses thereof for improvement of bone disordersAMOLYT PHARMA·Filed 2018·Granted Mar 16, 2021·0 cites·7 claims
- 1948US2004213792A1Method for inhibiting cellular activation by insulin-like growth factor-1Filed 2003·Application pending·0 cites
- 2033US11192932B2Heparin-binding domain of IGFBP-2 in the treatment of metabolic disordersAMOLYT PHARMA·Filed 2019·Granted Dec 7, 2021·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when David R. Clemmons files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →